CAY10404

CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities[1][2][3].

Product Specifications

CAS Number

[340267-36-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cay10404.html

Purity

99.69

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(C1=C(C2=CC=CC=C2)C(C3=CC=C(S(=O)(C)=O)C=C3)=NO1)(F)F

Molecular Formula

C17H12F3NO3S

Molecular Weight

367.34

Precautions

H302, H315, H319, H335

References & Citations

[1]A G Habeeb, et al. Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem. 2001 Aug 30;44 (18) :2921-7.|[2]Joshua A Robertson, et al. The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury. Am J Respir Cell Mol Biol. 2012 Sep;47 (3) :387-94.|[3]Yongseon Cho, et al. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells. Respirology. 2009 Aug;14 (6) :850-8.